The National Institute of Health and Care Excellence (NICE) has published new guidance for the month of June 2015. This month there are four guidelines and one technology appraisal that impact upon primary care.
The Suspected cancer: recognition and referral guideline offers evidence-based advice on the recognition of and referral for suspected cancer in children, young people and adults. This guideline is an update to CG27 published in June 2005.
The Lower urinary tract symptoms in men: assessment and management guideline offers evidence-based advice on the effective management of lower urinary tract symptoms (LUTS) in men. A new recommendation on phosphodiesterase-5 inhibitors has been added to section on drug treatment advising that these agents are not used solely for the purpose of treating lower urinary tract symptoms in men, except as part of a randomised controlled trial.
The Anaemia management in people with chronic kidney disease guideline offers evidence-based advice on diagnosing and managing anaemia of chronic kidney disease. This guideline is an update to CG114 published in February 2011.
The Workplace Health guideline makes recommendations on improving the health and wellbeing of employees, with a particular focus on organisational culture and context, and the role of line managers.
The Apixaban technology appraisal recommends this treatment, within its marketing authorisation, as an option for treating and preventing recurrent deep vein thrombosis or pulmonary embolism.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
|« Hypnotics and cancer risk concerns||Drug Safety Update - June 2015 »|